We are live on ! Find out more
HALO icon

Halozyme

201 hedge funds and large institutions have $1.95B invested in Halozyme in 2019 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 66 increasing their positions, 64 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

185% more call options, than puts

Call options by funds: $12.2M | Put options by funds: $4.28M

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

14% more capital invested

Capital invested by funds: $1.72B → $1.95B (+$233M)

3% more funds holding

Funds holding: 195201 (+6)

3% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 64

0.41% less ownership

Funds ownership: 83.8%83.4% (-0.41%)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
201
Holders Change
+6
Holders Change %
+3.08%
% of All Funds
4.35%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
25
Increased
66
Reduced
64
Closed
18
Calls
$12.2M
Puts
$4.28M
Net Calls
+$7.92M
Net Calls Change
+$1.92M

HALO Hedge Fund Activity: Q1 2019 in Review

201 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q1 2019, worth a combined $1.95B — up 14% from $1.72B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new HALO positions and 18 closed out — a net gain of 7 holders — while 66 added to existing stakes and 64 trimmed.

The largest buyer was Deutsche Bank, adding an estimated $9.35M. The largest seller was Iridian Asset Management, cutting an estimated $32.7M.

  • 201 institutional investors held Halozyme (HALO) as of Q1 2019, up from 195 in Q4 2018.
  • Funds reported $1.95B of Halozyme stock for Q1 2019, up 14% quarter-over-quarter.
  • 25 funds opened new Halozyme positions in Q1 2019 and 18 closed out, a net change of +7 holders.
  • The largest Halozyme buyer in Q1 2019 was Deutsche Bank, an estimated $9.35M added.
  • The largest Halozyme seller in Q1 2019 was Iridian Asset Management, an estimated $32.7M sold.

Based on aggregated 13F filings for Q1 2019.